

## **KURZPROTOKOLL** **OLE NEAT**

<b>Öffentlicher Titel</b>	Phase-3-Studie zu EryDex bei Patienten mit Louis-Bar-Syndrom nach Teilnahme an der Studie IEDAT-04-2022
<b>Wissenschaftl. Titel</b>	An Open-Label Extension Study of EryDex in Patients with Ataxia Teleangiectasia Following Participation in Study IEDAT-04-2022 (OLE NEAT)
<b>Kurztitel</b>	OLE NEAT
<b>Studienart</b>	multizentrisch, prospektiv, Therapiestudie, offen/unverblindet, einarmig, Pharma-Studie
<b>Studienphase</b>	Phase III
<b>Erkrankung</b>	Kinder: sonstige
<b>Einschlusskriterien</b>	<ul style="list-style-type: none"><li>- body weight 15 kg</li><li>- participation in IEDAT-04-2022 study and its completion, including final efficacy and safety assessments</li></ul>
<b>Ausschlusskriterien</b>	<ul style="list-style-type: none"><li>- safety contraindications for continuation of treatment, as determined by the investigator</li><li>- clinically significant immune impairment that, in the opinion of the Investigator, precludes further treatment with corticosteroids</li><li>- Current neoplastic disease or previous neoplastic disease not in remission for at least 2 years.</li><li>- requiring treatment with a systemic corticosteroid</li></ul>
<b>Alter</b>	>= 6 Jahre
<b>Sponsor</b>	Quince Therapeutics S.p.A.
<b>Registrierung in anderen Studienregistern</b>	EUCT 2024-513618-37-00 ClinicalTrials.gov NCT06664853
<b>Links</b>	<a href="#">Zu den Ein- und Ausschlusskriterien</a>